Acute and chronic administration of SHR117887, a novel and specific dipeptidyl peptidase-4 inhibitor, improves metabolic control in diabetic rodent models

Acta Pharmacologica Sinica

Volumn 33, Issue 8, 2012, Pages 1013-1022

  Liu, Xiao ^a   Zhang, Li Na ^a   Feng, Ying ^a   Zhang, Lei ^b   Qu, Hui ^a   Cao, Guo Qing ^b   Leng, Ying ^a  

^a SHANGHAI INSTITUTE OF MATERIA MEDICA   (China)

^b Hengrui Pharmaceutical Ltd   (China)

Author keywords

dipeptidyl peptidase 4 (DPP 4); glucagon like peptide 1 (GLP 1); insulin; SHR117887; type 2 diabetes mellitus; vildagliptin (LAF237); cells

Indexed keywords

5 [2 (2 CYANO 4 FLUOROPYRROLIDIN 1 YL) 2 OXOETHYLAMINOOXOETHYLAMINO] 5 METHYLHEXAHYDROCYCLOPENTA[C]PYRROLE 2 CARBOXYLIC ACID DIMETHYLAMIDE 4 TOLUENESULFONATE; DIPEPTIDYL PEPTIDASE IV; DIPEPTIDYL PEPTIDASE IV INHIBITOR; GLUCAGON LIKE PEPTIDE 1; GLUCOSE; INSULIN; ORAL ANTIDIABETIC AGENT; SHR 117887; UNCLASSIFIED DRUG; VILDAGLIPTIN; ANTIDIABETIC AGENT; GLUCOSE BLOOD LEVEL;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; BLOOD SAMPLING; CONTROLLED STUDY; DIABETES CONTROL; DIABETES MELLITUS; DOSE RESPONSE; DRUG DOSE COMPARISON; DRUG DOSE INCREASE; ENZYME ACTIVITY; ENZYME INHIBITION; GLUCOSE BLOOD LEVEL; IMMUNOHISTOCHEMISTRY; INSULIN BLOOD LEVEL; LIPID BLOOD LEVEL; MALE; METABOLIC PARAMETERS; METABOLIC REGULATION; MOUSE; NON INSULIN DEPENDENT DIABETES MELLITUS; NONHUMAN; ORAL GLUCOSE TOLERANCE TEST; PANCREAS ISLET BETA CELL; TREATMENT OUTCOME; ANIMAL; CHEMISTRY; DIABETES MELLITUS, TYPE 2; DISEASE MODEL; DRUG ADMINISTRATION; DRUG EFFECTS; INSTITUTE FOR CANCER RESEARCH MOUSE; METABOLISM; MOUSE MUTANT; RAT; WISTAR RAT;

ANIMALS; BLOOD GLUCOSE; DIABETES MELLITUS, TYPE 2; DIPEPTIDYL-PEPTIDASE IV INHIBITORS; DISEASE MODELS, ANIMAL; DRUG ADMINISTRATION SCHEDULE; HYPOGLYCEMIC AGENTS; MALE; MICE; MICE, INBRED ICR; MICE, OBESE; RATS; RATS, WISTAR;

EID: 84864677459     PISSN: 16714083     EISSN: 17457254     Source Type: Journal    
DOI: 10.1038/aps.2012.75     Document Type: Article

References (39)

1. Perley MJ, Kipnis DM. Plasma insulin responses to oral and intravenous glucose: studies in normal and diabetic subjects. J Clin Invest 1967; 46: 1954-62.
2. Bonora E. Protection of pancreatic beta-cells: is it feasible? Nutr Metab Cardiovasc Dis 2008; 18: 74-83. (Pubitemid 50020512)
3. Del Prato S, Penno G, Miccoli R. Changing the treatment paradigm for type 2 diabetes. Diabetes Care 2009; 32: 217-22.
4. Cefalu WT, Richards RJ, Melendez-Ramircz LY. Redefning treatment success in type 2 diabetes mellitus: comprehensive targeting of core defects. Cleve Clin J Med 2009; 76: 39-47.
5. Nauck MA, Vilsbøll T, Gallwitz B, Garber A, Madsbad S. Incretin-based therapies: viewpoints on the way to consensus. Diabetes Care 2009; 32: 223-31.
6. Tahrani AA, Piya MK, Kennedy A, Barnett AH. Glycaemic control in type 2 diabetes: targets and new therapies. Pharmacol Ther 2010; 125: 328-61.
7. Holst JJ. Therapy of type 2 diabetes mellitus based on the actions of glucagon-like peptide-1. Diabetes Metab Res Rev 2002; 18: 430-41. (Pubitemid 36041598)
8. Ahren B, Larsson H, Holst JJ. Effects of glucagon-like peptide-1 on islet function and insulin sensitivity in noninsulin-dependent diabetes mellitus. J Clin Endocrinol Metab 1997; 82: 473-8. (Pubitemid 27068614)
9. Willms B, Werner J, Holst JJ, Orskov C, Creutzfeldt W, Nauck MA. Gastric emptying, glucose responses and insulin secretion after a liquid test meal: effects of exogenous glucagon-like peptide-1 (GLP-1)-(7-36) amide in type 2 (noninsulin-dependent) diabetic patients. J Clin Endocrinol Metab 1996; 81: 327-32.
10. Naslund E, Barkeling B, King N, Gutniak M, Blundell JE, Holst JJ, et al. Energy intake and appetite are suppressed by glucagon-like peptide-1 (GLP-1) in obese men. Int J Obes Relat Metab Disord 1999; 23: 304-11. (Pubitemid 29118862)
11. D'Alessio DA, Kahn SE, Leusner CR, Ensinck JW. Glucagon-like peptide 1 enhances glucose tolerance both by stimulation of insulin release and by increasing insulin-independent glucose disposal. J Clin Investig 1994; 93: 2263-6. (Pubitemid 24143111)
12. Pospisilik JA, Martin J, Doty T, Ehses JA, Pamir N, Lynn FC, et al. Dipeptidyl peptidase IV inhibitor treatment stimulates cell survival and islet neogenesis in streptozotocin-induced diabetic rats. Diabetes 2003; 52: 741-50. (Pubitemid 36323582)
13. Drucker DJ. The biology of incretin hormones. Cell Metab 2006; 3: 153-65.
14. Farilla L, Bulotta A, Hirshberg B, Li Calzi S, Khoury N, Noushmehr H, et al. Glucagon-like peptide 1 inhibits cell apoptosis and improves glucose responsiveness of freshly isolated human islets. Endo crino-logy 2003; 144: 5149-58. (Pubitemid 37476040)
15. Mentlein R, Gallwitz B, Schmidt WE. Dipeptidyl-peptidase IV hydrolyses gastric inhibitory polypeptide, glucagon-like peptide-1 (7-36)amide, peptide histidine methionine and is responsible for their degradation in human serum. Eur J Biochem 1993; 214: 829-35. (Pubitemid 23188160)
16. Thomas L, Tadayyon M, Mark M. Chronic treatment with the dipeptidyl peptidase-4 inhibitor BI1356 (R)-8-(3-amino-piperidin-1-yl)-7-but-2-ynyl-3- methyl-1-(4-methyl-quinazolin-2-ylmethyl)-3,7-dihydro-purine-2,6-dione increases basal glucagon-like peptide-1 and improves glycemic control in diabetic rodent models. J Pharmacol Exp Ther 2009; 328: 556-63.
17. Yamazaki K, Yasuda N, Inoue T, Nagakura T, Kira K, Shinoda M, et al. 7-But-2-ynyl-9-(6-methoxy-pyridin-3-yl)-6-piperazin-1-yl-7,9-dihydro-purin-8- one is a novel competitive and selective inhibitor of dipeptidyl peptidase IV with an antihyperglycemic activity. J Pharmacol Exp Ther 2006; 319: 1253-7.
18. Augeri DJ, Robl JA, Betebenner DA, Magnin DR, Khanna A, Robertson JG, et al. Discovery and preclinical profle of saxagliptin (BMS-477118): a highly potent, long-acting, orally active dipeptidyl peptidase IV inhibitor for the treatment of type 2 diabetes. J Med Chem 2005; 48: 5025-37. (Pubitemid 41033142)
19. Moritoh Y, Takeuchi K, Asakawa T, Kataoka O, Odaka H. Chronic administration of alogliptin, a novel, potent, and highly selective dipeptidyl peptidase-4 inhibitor, improves glycemic control and beta-cell function in obese diabetic ob/ob mice. Eur J Pharmacol 2008; 588: 325-32.
20. Furuta Y, Horiguchi M, Sugaru E, Ono-Kishino M, Otani M, Sakai M, et al. Chronic administration of DSP-7238, a novel, potent, specifc and substrate-selective DPP IV inhibitor, improves glycaemic control and β-cell damage in diabetic mice. Diabetes Obes Metab 2010; 12: 421-30.
21. Thomas L, Eckhardt M, Langkopf E, Tadayyon M, Himmelsbach F, Mark M. (R)-8-(3-Amino-piperidin-1-yl)-7-but-2-ynyl-3-methyl-1-(4-methyl-quinazolin-2- ylmethyl)-3,7-dihydro-purine-2,6-dione (BI1356), a novel xanthine-based dipeptidyl peptidase 4 inhibitor, has a superior potency and longer duration of action compared with other dipeptidyl peptidase-4 inhibitors. J Pharmacol Exp Ther 2008; 325: 175-82. (Pubitemid 351439162)
22. Scott R, Wu M, Sanchez M, Stein P. Effcacy and tolerability of the dipeptidyl peptidase-4 inhibitor sitagliptin as monotherapy over 12 weeks in patients with type 2 diabetes. Int J Clin Pract 2007; 61: 171-80.
23. Pi-Sunyer FX, Schweizer A, Mills D, Dejager S. Effcacy and tolerability of vildagliptin monotherapy in drug-naive patients with type 2 diabetes. Diabetes Res Clin Practice 2007; 76: 132-8. (Pubitemid 46240373)
24. DeFronzo RA, Fleck PR, Wilson CA, Mekki Q. Effcacy and safety of the dipeptidyl peptidase-4 inhibitor alogliptin in patients with type 2 diabetes and inadequate glycemic control. Diabetes Care 2008; 31: 2315-7.
25. Villhauer EB, Brinkman JA, Naderi GB, Burkey BF, Dunning BE, Prasad K, et al. 1-(3-Hydroxy-1-adamantyl)aminoacetyl-2-cyano-(S)-pyrrolidine: a potent, selective and orally bioavailable dipeptidyl peptidase IV inhibitor with antihyperglycemic properties. J Med Chem 2003; 46: 2774-89. (Pubitemid 36702545)
26. Burkey BF, Li X, Bolognese L, Balkan B, Mone M, Russell M, et al. Acute and chronic effects of the incretin enhancer vildagliptin in insulin-resistant rats. J Pharmacol Exp Ther 2005; 315: 688-95. (Pubitemid 41500734)
27. Pratley RE, Salsali A. Inhibition of DPP-4: a new therapeutic approach for the treatment of type 2 diabetes. Curr Med Res Opin 2007; 23: 919-31. (Pubitemid 46631495)
28. Mitani H, Takimoto M, Hughes TE, Kimura M. Dipeptidyl peptidase IV inhibition improves impaired glucose tolerance in high-fat diet-fed rats: study using a Fischer 344 rat substrain defcient in its enzyme activity. Jpn J Pharmacol 2002; 88: 442-50.
29. Herberg L, Leiter EH. Obesity/diabetes in mice with mutations in the leptin or leptin receptor genes. In: Shima AAF, Shafrir E, editors. Animal models of diabetes a primer. Amsterdam: Harwood Academic Publishers; 2001. p 63-107.
30. Pederson RA, White HA, Schlenzig D, Pauly RP, McIntosh CH, Demuth HU. Improved glucose tolerance in Zucker fatty rats by oral administration of the dipeptidyl peptidase IV inhibitor isoleucine thiazolidide. Diabetes 1998; 47: 1253-8. (Pubitemid 28357002)
31. Balkan B, Kwasnik L, Miserendino R, Holst JJ, Li X. Inhibition of dipeptidyl peptidase IV with NVP-DPP728 increases plasma GLP-1 (7-36 amide) concentrations and improves oral glucose tolerance in obese Zucker rats. Diabetologia 1999; 42: 1324-31. (Pubitemid 29500969)
32. Ahren B, Holst JJ, Martensson H, Balkan B. Improved glucose tolerance and insulin secretion by inhibition of dipeptidyl peptidase IV in mice. Eur J Pharmacol 2000; 404: 239-45.
33. Mu J, Woods J, Zhou YP, Roy RS, Li Z, Zycband E, et al. Chronic inhibition of dipeptidyl peptidase-4 with a sitagliptin analog preserves pancreatic beta-cell mass and function in a rodent model of type 2 diabetes. Diabetes 2006; 55: 1695-704. (Pubitemid 44324122)
34. Moritoh Y, Takeuchi K, Asakawa T, Kataoka O, Odaka H. Chronic administration of alogliptin, a novel, potent, and highly selective dipeptidyl peptidase-4 inhibitor, improves glycemic control and beta-cell function in obese diabetic ob/ob mice. Eur J Pharmacol 2008; 588: 325-32.
35. Moritoh Y, Takeuchi K, Asakawa T, Kataoka O, Odaka H. Combining a dipeptidyl peptidase-4 inhibitor, alogliptin, with pioglitazone improves glycaemic control, lipid profles and β-cell function in db/db mice. Br J Pharmacol 2009; 157: 415-26.
36. Mu J, Woods J, Zhou YP, Roy RS, Li Z, Zycband E, et al. Chronic inhibition of dipeptidyl peptidase-4 with a sitagliptin analog preserves pancreatic beta-cell mass and function in a rodent model of type 2 diabetes. Diabetes 2006; 55: 1695-704. (Pubitemid 44324122)
37. Szayna M, Doyle ME, Betkey JA, Holloway HW, Spencer RG, Greig NH, et al. Exendin-4 decelerates food intake, weight gain, and fat deposition in Zucker rats. Endocrinology 2000; 141: 1936-41. (Pubitemid 32274340)
38. Moretto TJ, Milton DR, Ridge TD, Macconell LA, Okerson T, Wolka AM, et al. Efficacy and tolerability of exenatide monotherapy over 24 weeks in antidiabetic drug-naive patients with type 2 diabetes: a randomized, double-blind, placebo-controlled, parallel-group study. Clin Ther 2008; 30: 1448-60.
39. Feinglos MN, Saad MF, Pi-Sunyer FX, An B, Santiago O. Effects of liraglutide (NN2211), a long-acting GLP-1 analogue, on glycaemic control and body weight in subjects with type 2 diabetes. Diabet Med 2005; 22: 1016-23. (Pubitemid 41025998)